

Claims:

1. An anti-FcRn antibody or binding fragment thereof for use in the treatment or prevention of immune (idiopathic) thrombocytopenic purpura (ITP) in a human in need thereof, wherein the anti-FcRn antibody or binding fragment thereof is to be administered to the human in the range of 1 to 5 doses of the antibody or antigen binding fragment thereof over a treatment period of 1 to 12 weeks, wherein the aggregate dose in the treatment period is in the range of 1 to 30 mg per kg.
2. Use of an anti-FcRn antibody or antigen binding fragment thereof for the manufacture of a medicament for the treatment or prevention of immune (idiopathic) thrombocytopenic purpura (ITP), wherein the medicament is to be administered in the range of 1 to 5 doses of the antibody or binding fragment thereof over a treatment period of 1 to 12 weeks, wherein the aggregate dose in the treatment period is in the range of 1 to 30 mg per kg.
3. An anti-FcRn antibody or antigen binding fragment thereof or a use according to claim 1 or claim 2, wherein the antibody or binding fragment thereof comprises:
 - a. a heavy chain or heavy chain fragment having a variable region, wherein said variable region comprises three CDRs having the sequences given in SEQ ID NO: 1 for CDR H1, SEQ ID NO: 2 for CDR H2 and SEQ ID NO: 3 for CDR H3, and
 - b. a light chain or light chain fragment thereof having a variable region, wherein said variable region comprises three CDRs having the sequences given in SEQ ID NO: 4 for CDR L1, SEQ ID NO: 5 for CDR L2 and SEQ ID NO: 6 for CDR L3,
4. An anti-FcRn antibody or binding fragment thereof or a use according to any one of claims 1 to 3, wherein the antibody or antigen binding fragment thereof is humanized.
5. An anti-FcRn antibody or antigen binding fragment thereof or a use according to any one of claims 1 to 4 wherein the anti-FcRn antibody or binding fragment thereof comprises a heavy chain comprising the sequence given in SEQ ID NO:29 or a sequence specific to FcRn at least 80% identical thereto.
6. An anti-FcRn antibody or antigen binding fragment thereof or a use according to any one of claims 1 to 5 wherein the anti-FcRn antibody or binding fragment thereof comprises a light chain comprising the sequence given in SEQ ID NO:15 or a sequence specific to FcRn at least 80% identical thereto.
7. An anti-FcRn antibody or antigen binding fragment thereof or a use according to claim 3 or 4 wherein the anti-FcRn antibody or binding fragment thereof comprises a heavy chain variable domain sequence having the sequence given in SEQ ID NO:29 and a light chain variable domain sequence comprising the sequence given in SEQ ID NO:15.
8. An anti-FcRn antibody or antigen binding fragment thereof or a use according to any one of claims 1 to 7, wherein the antibody binding fragment is a scFv, Fv, Fab or Fab' fragment.

9. An anti-FcRn antibody or antigen binding fragment thereof or a use according to claim 8 wherein the anti-FcRn antibody or binding fragment thereof comprises a heavy chain comprising the sequence given in SEQ ID NO:36 and a light chain comprising the sequence given in SEQ ID NO:22.
- 5 10. An anti-FcRn antibody or a use according to any one of claims 1 to 6, wherein the antibody is a full length antibody.
11. An anti-FcRn antibody or a use according to claim 10 wherein the full length antibody is selected from the group consisting of an IgG1, IgG4 and IgG4P.
12. An anti-FcRn antibody or a use according to claim 10 or claim 11 wherein the anti-FcRn
10 antibody has a heavy chain comprising the sequence given in SEQ ID NO:72 or SEQ ID NO:87 or SEQ ID NO:43 and a light chain comprising the sequence given in SEQ ID NO:22.
13. An anti-FcRn antibody or a use according to claim 10, 11 or 12 wherein the anti-FcRn antibody is rozanolixizumab.
- 15 14. An anti-FcRn antibody or antigen binding fragment thereof or a use to any one of claims 1 to 7, wherein the antibody or binding fragment thereof is a Fab-dsFv having a heavy chain comprising the sequence given in SEQ ID NO:50 and a light chain comprising the sequence given in SEQ ID NO:46 or SEQ ID NO:78.
15. An anti-FcRn antibody or antigen binding fragment thereof or a use according to any one
20 of claims 1 to 14 having a binding affinity for human FcRn of 100pM or less.
16. An anti-FcRn antibody or antigen binding fragment thereof or a use according to claim 15 wherein the binding affinity for human FcRn is 100pM or less when measured at pH6 and at pH7.4.
17. An anti-FcRn antibody or antigen binding fragment thereof or a use according to any one
25 of claims 1 to 16 wherein the antibody or antigen binding fragment is provided as a pharmaceutical composition comprising one or more of a pharmaceutically acceptable excipient, diluent or carrier.
18. An anti-FcRn antibody or antigen binding fragment thereof or a use according to claim 17, wherein the pharmaceutical composition further comprises one or more other active
30 ingredients.
19. An anti-FcRn antibody or antigen binding fragment thereof or a use according to any one of claims 1 to 18, wherein the treatment is period is 1, 2, 3, 4, 5, 6, 7 or 8 weeks.
20. An anti-FcRn antibody or antigen binding fragment thereof or a use according to claim 19, wherein the treatment is period is 1, 2, 3, 4 or 5 weeks.
- 35 21. An anti-FcRn antibody or antigen binding fragment thereof or a use according to any one of claims 1 to 20, wherein 1, 2, 3, 4 or 5 doses of antibody or binding fragment are to be administered and each dose is in the range of 4mg/kg to 30 mg/kg.
22. An anti-FcRn antibody or antigen binding fragment thereof or a use according to claim 21, wherein each dose is 4mg/Kg, for example to be administered as five individual
40 doses, in particular over a treatment period of five weeks, in particular five consecutive weeks.

23. An anti-FcRn antibody or antigen binding fragment thereof or a use according to claim 21, wherein each dose is 7mg/Kg, for example to be administered as three individual doses, in particular over a treatment period of three weeks, in particular three consecutive weeks.
- 5 24. An anti-FcRn antibody or antigen binding fragment thereof or a use according to claim 21, wherein each dose is 10mg/Kg, for example to be administered as two individual doses, in particular over a treatment period of two weeks, in particular two consecutive weeks.
25. An anti-FcRn antibody or antigen binding fragment thereof or a use according to claim 10 21, wherein a single dose is to be administered.
26. An anti-FcRn antibody or antigen binding fragment thereof or a use according to claim 25 wherein the dose is 15mg/Kg.
27. An anti-FcRn antibody or antigen binding fragment thereof or a use according to claim 25, wherein the dose is 20mg/Kg.
- 15 28. An anti-FcRn antibody or antigen binding fragment thereof or a use according to claim 25, wherein the dose is 25mg/Kg.
29. An anti-FcRn antibody or antigen binding fragment thereof or a use according to claim 25, wherein the dose is 30mg/Kg.
30. An anti-FcRn antibody or antigen binding fragment thereof or a use according to any one 20 of claims 1 to 29 wherein the aggregate dose is selected from 10, 15, 20, 21, 25 and 30 mg/Kg.
31. An anti-FcRn antibody or antigen binding fragment thereof or a use according to any one of claims 1 to 30 wherein the anti-FcRn antibody or binding fragment thereof is to be administered subcutaneously or intravenously.
- 25 32. An anti-FcRn antibody or antigen binding fragment thereof or a use according to any one of claims 1 to 31 wherein the an anti-FcRn antibody or antigen binding fragment thereof blocks binding of human IgG to human FcRn.
33. An anti-FcRn antibody or antigen binding fragment thereof or a use according to any one of claims 1 to 32 wherein the an anti-FcRn antibody or antigen binding fragment thereof 30 does not bind β 2 microglobulin.
34. An anti-FcRn antibody or antigen binding fragment thereof or a use according to any one of claims 1 to 33 wherein the medicament is to be further administered one or more additional doses that are lower than the initial dose.